(Q37200990)

18 August 2017

1 reference

title

Targeting the COPD exacerbation (English)

1 reference

18 August 2017

7

Thierry Troosters

1 reference

18 August 2017

1

Marc Decramer

1 reference

18 August 2017

5

Carolyn L Rochester

1 reference

18 August 2017

Linda Nici

2

1 reference

18 August 2017

Stefano Nardini

series ordinal

3

1 reference

18 August 2017

Jane Reardon

series ordinal

4

1 reference

18 August 2017

Claudio M Sanguinetti

series ordinal

6

1 reference

18 August 2017

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

102 Suppl 1

1 reference

18 August 2017

page(s)

S3-15

1 reference

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Risk factors of readmission to hospital for a COPD exacerbation: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Airway eosinophilia in chronic bronchitis during exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

A qualitative evaluation of a comprehensive self-management programme for COPD patients: effectiveness from the patients' perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Self-management reduces both short- and long-term hospitalisation in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Economic benefits of self-management education in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

The effects of education alone and in combination with pulmonary rehabilitation on self-efficacy in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Heart failure and chronic obstructive pulmonary disease: An ignored combination?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Cardiopulmonary stress during exercise training in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Improvement in quadriceps strength and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Early mobilization with walking aids following hospital admission with acute exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Mechanisms of improvement in exercise capacity using a rollator in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Exercise training improves recovery in patients with COPD after an acute exacerbation

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Physical activity and hospitalization for exacerbation of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Integrated care prevents hospitalisations for exacerbations in COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Cardiovascular safety of salmeterol in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Tiotropium for stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immuno

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón)

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2970003-9

7 January 2021

10.1016/S0954-6111(08)70003-9

Identifiers

DOI

1 reference

18 August 2017

1 reference